Efficacy of the Bisphosphonate Alone and Combined with Paclitaxel Against Bone Metastasis of Human Adenocarcinoma Lung Cancer

周箴,杨顺芳,何卫中,陆舜

DOI: https://doi.org/10.3969/j.issn.1007-3639.2008.05.008

2008-01-01

Abstract:Background and purpose:Zoledronic acid has been proved to have anti-tumour effects.The purpose of this study was to establish a human lung adenocarcinoma cell line(SPC-A-1BM)with high metastatic potential in bone of immunodeficient(SCID)mouse model,and to evaluate the efficacy of zoledronate alone and combined with paclitaxel in reducing the tumor-induced bone disease.Methods:The human lung adenocarcinoma cancer cells SPC-A-1BM were inoculated into the cardiac ventricle of 40 SCID mice(NIH-BNX).They were randomized into 4 groups,and were treated with zoledronate alone,zoledronate combined with paclitaxel,or paclitaxel alone,or control group,respectively for 5 weeks after 7 days of tumor implantation.Bone metastases was assessed,measurement of total-body nuclei bone scan,X-rays,serum NTx were done,bone lesions for pathologic evaluation,the incidence of other organ metastasis,weight loss and survival time until 8 weeks were also analyzed.Results:The zoledronate combined with paclitaxel was very effective in reducing NSCLC bone metastases.Bone nuclei scan,radiographic and histological results revealed that there were more bone metastatic lesions in the control group than that in the treatment group.In the treatment groups,bone nuclei scan and radiographic imagine suggested that the combined group significantly reduced bone metastasis(P=0.013,P=0.036).Histological analysis showed that there was a marginal difference(P=0.058)between the combined group and the control.The numbers of bone metastases mice in combined group equaled to that in the paclitaxel group,there were less bone metastases than the control's.Moreover,the bone turnover biomarker NTx level was reduced by inhibiting osteoclast activity in the combined group,there was a significant difference between the control and paclitaxel group,respectively(P=0.017,P=0.022).The combined group inhibited lung metastases(P=0.036).Only the combined group significantly prolonged the survival time(log rank=0.022).Conclusions:The results indicated that zoledronate inhibited the osteoclast activity,zoledronate enhanced the effects of paclitaxel synergistically,reduced the incidence of NSCLC bone metastasis and prolonged survival time.